Serum HER‐2/neu and relative resistance to trastuzumab‐based therapy in patients with metastatic breast cancer

@article{Ali2008SerumHA,
  title={Serum HER‐2/neu and relative resistance to trastuzumab‐based therapy in patients with metastatic breast cancer},
  author={S. Ali and W. Carney and F. Esteva and M. Fornier and L. Harris and W. K{\"o}stler and J. Lotz and D. Luftner and Marie-France Pichon and A. Lipton},
  journal={Cancer},
  year={2008},
  volume={113}
}
  • S. Ali, W. Carney, +7 authors A. Lipton
  • Published 2008
  • Medicine
  • Cancer
  • Previous reports based on small patient numbers suggested that changes in serum HER‐2/neu levels may predict response or lack of response to trastuzumab‐based therapies in metastatic breast cancer (MBC). The objectives of this study were to pool data from 307 patients with MBC from 7 medical institutions to validate that the serum HER‐2/neu profile predicts patient resistance to trastuzumab and to establish a clinically relevant cutoff. 
    86 Citations

    Topics from this paper

    Personalizing HER2-targeted therapy in metastatic breast cancer beyond HER2 status: what we have learned from clinical specimens.
    • 63
    • Highly Influenced
    Biomarkers of Therapeutic Resistance in Breast Cancer
    Primary trastuzumab resistance: new tricks for an old drug
    • 58

    References

    SHOWING 1-10 OF 44 REFERENCES
    HER-2-targeted therapy: lessons learned and future directions.
    • R. Nahta, F. Esteva
    • Medicine
    • Clinical cancer research : an official journal of the American Association for Cancer Research
    • 2003
    • 188
    • PDF
    Monitoring of Serum Her-2/neu Predicts Response and Progression-Free Survival to Trastuzumab-Based Treatment in Patients with Metastatic Breast Cancer
    • 152
    • PDF
    Herceptin: mechanisms of action and resistance.
    • 418
    • PDF
    Circulating HER2 extracellular domain and resistance to chemotherapy in advanced breast cancer.
    • 175
    • PDF
    Potential clinical utility of serum HER-2/neu oncoprotein concentrations in patients with breast cancer.
    • 166
    • PDF
    USE OF CHEMOTHERAPY PLUS A MONOCLONAL ANTIBODY AGAINST HER 2 FOR METASTATIC BREAST CANCER THAT OVEREXPRESSES HER 2
    • 1,024
    • PDF